Dynamics of Inhaled Tobramycin Concentration in Blood and Bronchoalveolar Lavage Fluid during Nosocomial Pneumonia (Preliminary Report)
https://doi.org/10.15360/1813-9779-2018-5-32-37
Abstract
This study was aimed to evaluate the dynamics of inhaled tobramycin concentration in bronchoalveolar lavage fluid and blood in victims with nosocomial pneumonia.
Materials and Methods. The study is presented as a series of clinical observations: 5 patients with severe concomitant craniocerebral injury were included, who were treated in the general resuscitation unit (men 4 (87.5%), women 1 (12.5%); age 36Ѓ}12 years; Injury Severity Score (ISS) 40.9Ѓ}8.3; acute blood loss volume 2356Ѓ}997 ml; mean bed-days 12.50 days; mortality 16.7%). Statistical analysis of data obtained was carried out using Statistica 10.0 software. Difference was considered significant at p<0.05.
Results. The dynamics of tobramycin concentrations was as follows: 1 hr. blood/BAL 0.96Ѓ}0.44 μg/ml / 49.6 μg/ml; 3 hrs. blood/BAL 0.98Ѓ}0.82 μg/ml / 15.5 μg/ml; 5 hrs. blood/BAL 0.79Ѓ}0.83 μg/ml / 3.5 μg/ml.
Conclusion.The results obtained confirm significant local concentrations of tobramycin in sputum and low in blood, which corresponds to the results of pharmacokinetic studies and clinical studies of inhaled tobramycin efficacy. At present, gathering of material for the study continues.
About the Authors
A. N. Kuzovlev
V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
Russian Federation
Russian Federation
Artem N. Kuzovlev
25 Petrovka Str., Bldg. 2, 107031 Moscow
A. K. Shabanov
V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology;
N. V. Sklifosovsky Research Institute of Emergency Medicine
Russian Federation
Russian Federation
Aslan K. Shabanov
25 Petrovka Str., Bldg. 2, 107031 Moscow,
3 Bolshaya Sukharevskaya Square, 129090 Moscow
I. А. Tyurin
N. V. Sklifosovsky Research Institute of Emergency Medicine
Russian Federation
Russian Federation
Igor A. Tyurin
3 Bolshaya Sukharevskaya Square, 129090 Moscow
References
1. Gelfand B.R. (ed.). Nosocomial pneumonia in adults. Russian national guidelines. 2-nd ed. Moscow: Meditsinskoe Informatsionnoe Agentstvo; 2016: 176. ISBN 978-5-9986-0284-9. [In Russ.]
2. Kuzovlev A.N., Grechko A.V. Inhaled antibiotics in reanimatology: problem state and development prospects (review). Obshchaya Reanimatologiya = General Reanimatology. 2017; 13 (5): 69-84. DOI: 10.15360/1813-9779-2017-5-69-84. [In Russ., In Engl.]
3. Kuzovlev A.N., Moroz V.V., Golubev A.M. Inhaled antibiotics in treatment of nosocomial pneumonia. Anesteziologiya i Reanimatologiya. 2015; 60 (4): 55-61. PMID: 26596034. [In Russ.]
4. Rello J., Solé-Lleonart C., Rouby J., Chastre J., Blot S., Poulakou G., Luyt C., Riera J., Palmer L., Pereira J., Felton T., Dhanani J., Bassetti M., Welte T., Roberts J. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin. Microbiol. Infect. 2017; 23 (9): 629-639. DOI: 10.1016/j.cmi.2017.04.011. PMID: 28412382
5. Khubutiya M.Sh., Shabanov A.K., Chernenkaya T.V., Tarabrin E.A., Kuzovlev A.N. Early administration of inhaled tobramycin to victims with severe multiple trauma. Pulmonologiya. 2015; 25 (2): 211-216. [In Russ.]
6. Bos A.C., Mouton J.W., van Westreenen M., Andrinopoulou E.R., Janssens H.M., Tiddens H.A.W.M. Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily? J. Antimicrob. Chemother. 2017; 72 (12): 3435-3442. DOI: 10.1093/jac/dkx293. PMID: 29029057
7. Falagas M.E., Trigkidis K.K., Vardakas K.Z. Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: a systematic review. Int. J. Antimicrob. Agents. 2015; 45 (3): 221–233. DOI: 10.1016/j.ijantimicag.2014.10.008. PMID: 25533880
8. Li M., Byron P.R. Tobramycin disposition in the rat lung following airway administration. J. Pharmacol. Exp. Ther. 2013; 347 (2): 318-324. DOI: 10.1124/jpet.113.207415. PMID: 24008335
9. Marchand S., Grégoire N., Brillault J., Lamarche I., Gobin P., Couet W. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 3. Tobramycin. Antimicrob. Agents Chemother. 2015; 59 (10): 66466647. DOI: 10.1128/AAC.01647-15. PMID: 26239992
10. Griese M., Eismann C., Börner G., Denk O., Schierholz J.M., Keller M., Mazurek H., Kappler M. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI. J. Aerosol. Med. Pulm. Drug Deliv. 2014; 27 (3): 185-192. DOI: 10.1089/jamp.2012.1022. PMID: 23789705
11. van Velzen A.J., Bos A.C., Touw D.J., Tiddens H.A., Heijerman H.G., Janssens H.M. Pharmacokinetics and tolerability of once daily double dose tobramycin inhalation in cystic fibrosis using controlled and conventional nebulization. J. Aerosol. Med. Pulm. Drug Deliv. 2016; 29 (3): 273-280. DOI: 10.1089/jamp.2015.1259. PMID: 26716357
12. Orizondo R.A., Fabiilli M.L., Morales M.A., Cook K.E. Effects of emulsion composition on pulmonary tobramycin delivery during antibacterial perfluorocarbon ventilation. J. Aerosol. Med. Pulm. Drug Deliv. 2016; 29 (3): 251-259. DOI: 10.1089/jamp.2015.1235. PMID: 26741303
13. Hoppentocht M., Akkerman O.W., Hagedoorn P., Alffenaar J.W., van der Werf T.S., Kerstjens H.A., Frijlink H.W., de Boer A.H. Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. PLoS One. 2016; 11 (3): e0149768. DOI: 10.1371/journal.pone.0149768. PMID: 26959239
Review
For citations:
Kuzovlev A.N., Shabanov A.K., Tyurin I.А. Dynamics of Inhaled Tobramycin Concentration in Blood and Bronchoalveolar Lavage Fluid during Nosocomial Pneumonia (Preliminary Report). General Reanimatology. 2018;14(5):32-37. https://doi.org/10.15360/1813-9779-2018-5-32-37
Views:
1156
Email this article 